Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Saad Z. Usmani"'
Autor:
Jordan M. Schecter, Carolyn C. Jackson, Arnob Banerjee, Saad Z. Usmani, Lida Bubuteishvili Pacaud, Tzu-Min Yeh, Joris Diels, Imtiaz A. Samjoo, Anja Haltner, Martin Vogel, William Deraedt, Suzy Van Sanden, Hong Tian, Chris Cameron, Satish Valluri, Thomas Martin, Ashraf Garrett
Publikováno v:
Current Medical Research and Opinion. 37:1779-1788
OBJECTIVE This study estimated the comparative efficacy of ciltacabtagene autoleucel (cilta-cel) versus the approved idecabtagene vicleucel (ide-cel) dose range of 300-460 × 106 CAR-positive T-cells for the treatment of patients with relapsed or ref
Autor:
Deepa Dongarwar, Premal Lulla, Helen E. Heslop, Saad Z. Usmani, Samer Al Hadidi, George Carrum, Rammurti T. Kamble, Carlos A. Ramos, Hamisu M. Salihu, La Quisa C. Hill
Publikováno v:
Leuk Lymphoma
Hispanics and non-Hispanic (NH)-Blacks continue to face numerous health disparities related to multiple myeloma (MM). We aimed to analyze trends of MM-related hospitalizations and incidence of in-hospital mortality with a 10-year cross-sectional anal
Publikováno v:
ImmunoTargets and Therapy
The survival outcomes for multiple myeloma have improved several-fold in the past two decades, primarily due to the introduction of therapies with novel mechanisms of action including immunomodulatory agents, proteasome inhibitors, stem cell transpla
Autor:
Saad Z. Usmani, Zeena Salman, Lipo Chang, Robert F. Cornell, Beata Holkova, Yihua Lee, Larry D. Anderson, Elizabeth Bilotti, Chatchada Karanes, Cristina Gasparetto, Yvonne Pak, Ruben Niesvizky, Jason Valent, Sarah Larson, Thorsten Graef, Jeffrey Matous, Saurabh Chhabra, Ajai Chari, Matthew A. Lunning
Publikováno v:
Leukemia & Lymphoma. 59:2588-2594
This phase 1, dose-finding study investigated ibrutinib and carfilzomib ± dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (≥2 lines of therapy including bortezomib and an immunomodulatory agent). Of 43 patients enro
Publikováno v:
Drug Design, Development and Therapy
Elotuzumab is one of the first monoclonal antibodies to be approved for the treatment of multiple myeloma. It is a humanized immunoglobulin G kappa (IgGκ) antibody that targets signaling lymphocytic activation molecule family member 7 (SLAMF7), a su
Autor:
Sham Mailankody, Liza Lindenberg, Elizabeth Lamping, Peter L. Choyke, Marcia Mulquin, Neha Korde, Mary Kwok, Esther Mena, Katherine R. Calvo, Baris Turkbey, Manisha Bhutani, Alex Minter, Esther Tan, Mark Roschewski, Brendan M. Weiss, Saad Z. Usmani, Nishant Tageja, Irina Maric, Karen A. Kurdziel, Ashley Carpenter, Elisabet E. Manasanch, Ola Landgren
Publikováno v:
Leukemia & Lymphoma. 57:1114-1121
The incidence and importance of bone marrow involvement and/or early bone lesions in multiple myeloma (MM) precursor diseases is largely unknown. This study prospectively compared the sensitivity of several imaging modalities in monoclonal gammopathy
Autor:
Saad Z. Usmani
Publikováno v:
Expert Review of Hematology. 7:17-19
Evaluation of: Mateos MV, Hernandez MT, Giraldo P, et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med 2013;369:438-47Smoldering or asymptomatic multiple myeloma may be best described as a state of limbo whe